JP5444239B2 - タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体 - Google Patents

タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体 Download PDF

Info

Publication number
JP5444239B2
JP5444239B2 JP2010532265A JP2010532265A JP5444239B2 JP 5444239 B2 JP5444239 B2 JP 5444239B2 JP 2010532265 A JP2010532265 A JP 2010532265A JP 2010532265 A JP2010532265 A JP 2010532265A JP 5444239 B2 JP5444239 B2 JP 5444239B2
Authority
JP
Japan
Prior art keywords
independently
group
halogen
compound
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010532265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502994A (ja
JP2011502994A5 (2
Inventor
ホアン−ミゲル ヒメネス，
マイケル モーティモア，
フィリップ コリアー，
アンドリュー ミラー，
スティーブン ヤング，
チョウ マク，
クリストファー デイビス，
ヘザー ツイン，
ガイ ブレンチリー，
ディーン ボヤール，
シャジア カイリー，
ルカ セティモ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2011502994A publication Critical patent/JP2011502994A/ja
Publication of JP2011502994A5 publication Critical patent/JP2011502994A5/ja
Application granted granted Critical
Publication of JP5444239B2 publication Critical patent/JP5444239B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2010532265A 2007-11-02 2008-10-31 タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体 Expired - Fee Related JP5444239B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98487507P 2007-11-02 2007-11-02
US60/984,875 2007-11-02
US4457508P 2008-04-14 2008-04-14
US61/044,575 2008-04-14
US10080808P 2008-09-29 2008-09-29
US61/100,808 2008-09-29
PCT/US2008/081933 WO2009073300A1 (en) 2007-11-02 2008-10-31 [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta

Publications (3)

Publication Number Publication Date
JP2011502994A JP2011502994A (ja) 2011-01-27
JP2011502994A5 JP2011502994A5 (2) 2012-12-13
JP5444239B2 true JP5444239B2 (ja) 2014-03-19

Family

ID=40220120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532265A Expired - Fee Related JP5444239B2 (ja) 2007-11-02 2008-10-31 タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体

Country Status (16)

Country Link
US (2) US8173635B2 (2)
EP (1) EP2215089B1 (2)
JP (1) JP5444239B2 (2)
KR (1) KR20100093552A (2)
CN (1) CN101903384A (2)
AR (1) AR069174A1 (2)
AU (1) AU2008331733A1 (2)
CA (1) CA2704266A1 (2)
CL (1) CL2008003280A1 (2)
ES (1) ES2389992T3 (2)
IL (1) IL205458A0 (2)
MX (1) MX2010004819A (2)
NZ (1) NZ585063A (2)
TW (1) TW200924762A (2)
WO (1) WO2009073300A1 (2)
ZA (1) ZA201003050B (2)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3456189B2 (ja) 2000-03-31 2003-10-14 日本電気株式会社 移動通信システム
UA95940C2 (uk) 2006-01-17 2011-09-26 Вертекс Фармасьютикалс Інкорпорейтед Азаіндоли як інгібітори кіназ януса
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
TW200924762A (en) 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors
JP2011513483A (ja) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
CA2732765A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
SG174214A1 (en) 2009-03-25 2011-10-28 Abbott Lab Antiviral compounds and uses thereof
CA2760705A1 (en) * 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
LT3141252T (lt) 2009-06-17 2018-11-12 Vertex Pharmaceuticals Inc. Gripo virusų replikacijos inhibitoriai
EP2582702A1 (en) 2010-01-27 2013-04-24 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
JP5769733B2 (ja) * 2010-01-27 2015-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ピラゾロピリジンキナーゼ阻害剤
MX2012008642A (es) * 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
CA2787079A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
CN102471342A (zh) * 2010-05-05 2012-05-23 沃泰克斯药物股份有限公司 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
CN103562205A (zh) 2010-12-16 2014-02-05 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
CA2822059A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
US9523045B2 (en) 2013-01-30 2016-12-20 Ecolab Usa Inc. Hydrogen sulfide scavengers
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
JP6618901B2 (ja) 2013-11-13 2019-12-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
US9556126B2 (en) 2013-12-20 2017-01-31 Signal Pharmaceuticals, Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP3197450A1 (en) 2014-09-22 2017-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of fibrosis
AU2016250539B2 (en) 2015-04-22 2020-06-11 Championx Usa Inc. Development of a novel high temperature stable scavenger for removal of hydrogen sulfide
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2017044248A1 (en) 2015-09-08 2017-03-16 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10407626B2 (en) 2015-09-08 2019-09-10 Ecolab Usa Inc. Hydrocarbon soluble/dispersible hemiformals as hydrogen sulfide scavengers
EP3491106B1 (en) 2016-07-29 2020-07-15 Ecolab Usa Inc. Antifouling and hydrogen sulfide scavenging compositions
CR20190119A (es) * 2016-09-09 2019-06-03 Novartis Ag Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
US10538710B2 (en) 2017-07-13 2020-01-21 Ecolab Usa Inc. Hydrogen sulfide scavengers
EP3914676A1 (en) 2019-01-23 2021-12-01 ChampionX USA Inc. Complete removal of solids during hydrogen sulfide scavenging operations using a scavenger and a michael acceptor
CA3136348A1 (en) * 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
CN111529533B (zh) * 2020-06-05 2021-06-11 南华大学附属第一医院 溴结构域蛋白4抑制剂jq1或其衍生物在制备治疗脓毒症肠屏障损伤药物中的应用
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators
PE20250019A1 (es) * 2021-05-06 2025-01-07 Exscientia Ai Ltd MODULADORES DE PKC-theta

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2080531A (en) * 1936-01-08 1937-05-18 United Shoe Machinery Corp Manufacture of shoes
US3314941A (en) * 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
GB1159487A (en) 1968-04-04 1969-07-23 Standard Telephones Cables Ltd Capacitors
US4988705A (en) * 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
JP2890448B2 (ja) 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5100768A (en) * 1989-05-09 1992-03-31 Kabushiki Kaisha Toshiba Photosensitive composition
JPH03206450A (ja) * 1990-01-09 1991-09-09 Fuji Photo Film Co Ltd 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法
JPH03271289A (ja) 1990-03-16 1991-12-03 Nissan Chem Ind Ltd ピラゾロピリジン誘導体の製造法及びジヒドロピラゾロピリジン誘導体
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
US5646330A (en) * 1995-02-17 1997-07-08 Ciba-Geigy Corporation Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols
US6194581B1 (en) * 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6452008B2 (en) * 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
GB9908410D0 (en) * 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AR029289A1 (es) * 2000-07-05 2003-06-18 Ishihara Sangyo Kaisha Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo
JP2002020386A (ja) 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
DE10035908A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
JP2005516927A (ja) * 2001-12-13 2005-06-09 アボット・ラボラトリーズ 癌治療用のキナーゼ阻害剤としての３−（フェニル−アルコキシ）−５−（フェニル）−ピリジン誘導体および関連化合物
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
DE10222550A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
JPWO2004002531A1 (ja) * 2002-06-26 2005-10-27 小野薬品工業株式会社 血管の収縮または拡張による疾患治療剤
EP1545515A1 (en) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US20040242613A1 (en) * 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
CA2518398A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
US20050203067A1 (en) * 2003-05-12 2005-09-15 Hresko Michelle C. Pesticidal compositions and methods
EP1660087A2 (en) * 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
JP4805166B2 (ja) * 2003-12-22 2011-11-02 バジリア ファルマスーチカ アーゲー アロイルフランおよびアロイルチオフェン
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
ATE554087T1 (de) * 2004-10-29 2012-05-15 Abbott Lab Neue kinaseinhibitoren
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
EP1812450A2 (en) 2004-11-10 2007-08-01 Eli Lilly And Company Tgf-beta inhibitors
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
RU2387653C2 (ru) * 2005-05-16 2010-04-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
US7846941B2 (en) 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
DE102005035417A1 (de) 2005-07-28 2007-02-01 Robert Bosch Gmbh Entfernungsmessgerät und Verfahren zum Befestigen einer elektrooptischen Einheit an einer Leiterträgereinheit
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
DE102005048897A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2007076423A2 (en) 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITORS OF Akt ACTIVITY
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
DK3421471T3 (da) * 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
TW200815438A (en) 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
JP2008132121A (ja) * 2006-11-28 2008-06-12 Sanshin Kinzoku Kogyo Kk 移動ラック装置
EP2118088B1 (en) 2006-12-20 2012-05-30 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
WO2008132121A1 (en) * 2007-04-26 2008-11-06 Glaxo Group Limited Lh-indazole-3-amine compounds as ikk1 inhibitors
TW200924762A (en) 2007-11-02 2009-06-16 Vertex Pharma Kinase inhibitors

Also Published As

Publication number Publication date
US20090291937A1 (en) 2009-11-26
JP2011502994A (ja) 2011-01-27
ZA201003050B (en) 2011-07-27
CN101903384A (zh) 2010-12-01
US8173635B2 (en) 2012-05-08
WO2009073300A1 (en) 2009-06-11
EP2215089A1 (en) 2010-08-11
MX2010004819A (es) 2010-07-05
CL2008003280A1 (es) 2010-01-04
ES2389992T3 (es) 2012-11-05
EP2215089B1 (en) 2012-06-27
IL205458A0 (en) 2010-12-30
TW200924762A (en) 2009-06-16
KR20100093552A (ko) 2010-08-25
US8367697B2 (en) 2013-02-05
CA2704266A1 (en) 2009-06-11
AU2008331733A1 (en) 2009-06-11
US20120149680A1 (en) 2012-06-14
AR069174A1 (es) 2010-01-06
NZ585063A (en) 2012-05-25

Similar Documents

Publication Publication Date Title
JP5444239B2 (ja) タンパク質キナーゼＣ−θとしての［１Ｈ−ピラゾロ［３，４−Ｂ］ピリジン−４−イル］−フェニレンまたは−ピリジン−２−イル誘導体
US9029546B2 (en) Pyrazolopyridine kinase inhibitors
JP5627675B2 (ja) ピラゾロピリジン
EP2328896B1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
US20120165368A1 (en) Pyrazolopyridine kinase inhibitors
JP2013525481A (ja) ＰＫＣ−θインヒビターとして有用な４置換ピラゾロピリミジン
WO2011094273A1 (en) Pyrazolopyridine kinase inhibitors
US8895740B2 (en) Pyrazolopyrazine kinase inhibitors
JP2013518114A (ja) ピラゾロピリミジンキナーゼ阻害剤
MX2011011712A (es) Pirazolopirimidinas 4-sustituidas utiles como inhibidores de pkc-theta.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131220

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees